2013-635 - Programme
- 1. 1 1st World Lung Disease Summit Supported by an unrestricted educational grant from Almirall S.A. “Highlights and hot topics in the management of COPD: where are we heading?” Dental Medicine University, Lisbon, 15th -17th November 2013 Overall objectives of the closed symposium The main objectives of this World Lung Disease Summit are to: • Explore many of the issues and challenges faced by clinicians associated with COPD, including recent advances and developments in disease management • Review recently published data and current hot topics in COPD • Discuss and share experiences on relevant everyday aspects of the clinical management of patients with COPD Target audience - ~700 international pulmonologists, primary care and secondary care respiratory physicians (ex-US) Scientific Committee • Professor Alvar Agusti (Spain) • Professor Paul Jones (UK) • Professor Claus Vogelmeier (Germany) Faculty Confirmed faculty are as follows: • Co-chair: Professor Alvar Agusti (Spain) • Co-chair: Professor Paul Jones (UK) • Professor Peter Lange (Denmark) • Dr Neil Barnes (UK) TBC • Professor Denis O’Donnell (Canada) • Professor William MacNee (UK) • Professor Henrik Watz (Germany) • Professor Emiel Wouters (The Netherlands) • Professor Mario Cazzola (Italy)
- 2. 2 • Professor Wisia Wedzicha (UK) • Professor Ian Pavord (UK) • Professor Pierre R. Burgel (France) • Professor Klaus Rabe (Germany) Detailed overview This 2-day meeting for international respiratory pulmonologists and physicians with a specialty in the management of patients with COPD will provide an update on the latest research in influential areas informing the diagnosis and management of patients with COPD. The meeting programme has been developed in consultation with the Scientific Committee. The plenary sessions will be presented by experts in research and interpretation of evidence in the following areas: clinical features differentiating COPD and asthma, lung function and exercise assessments, prevention and treatment of COPD symptoms, rehabilitation and personalised medicine, the importance of delivery systems, and exacerbation of COPD. The presenters will discuss how this information and knowledge could influence clinical management and outcomes in COPD. The presentations will encourage involvement and opportunities for discussion with delegates on current opinions and knowledge via question cards, as well as live question and answer sessions from the floor to the faculty. There will be on site translation included in five different languages (French, German, Italian, Polish and Spanish). Evaluation forms will be collected after the meeting, to provide evidence of delegate participation and achievement of learning objectives. There will be an interactive display educating delegates on lung physiology in health lungs versus those with COPD, and a poster session with posters that present recently published clinical data on the management of COPD. Attendees will be asked to rank the studies according to relevance to and implications for their everyday clinical practice. Proceedings from the sessions over the two-day period, authored by the speakers and chairmen, will be developed after the event and circulated to all attendees. This will include summaries of the latest information presented and the session outputs (including key issues raised by the attendees in question and answer session, poster rankings and evaluation questionnaires).
- 3. 3 Learning objectives for each session are summarised here: Day 2: Saturday 16 November 2013 (morning sessions) Session Learning objectives Module 1: Diagnosis and assessment of COPD: beyond FEV1 COPD and asthma are different diseases Professor Peter Lange (Denmark) - Be able to identify the most important differential characteristics of COPD versus asthma with regard to medical history, comorbidities, clinical presentation, lung function abnormalities, imaging and currently available biomarkers - Be able to integrate these parameters in order to make the most likely diagnosis in a patient presenting with respiratory symptoms - Acknowledge the importance of differentiating between asthma and COPD in daily clinical practice and to relate this to differences in treatment options and clinical prognosis COPD and asthma are some of the same Dr Neil Barnes (UK) TBC - To understand that airway disease is complex and that there can be significant overlap between the pathophysiological and clinical characteristics of COPD and asthma - To understand the similarities in clinical characteristics between COPD and asthma, the different mechanisms underlying these characteristics and how these may impact on future strategies for management of airway disease - To understand the importance of assessing patients according to their individual clinical characteristics in order to identify the most appropriate, personalized, treatment options Lung function and exercise tests – which methods tells us what? Professor Denis O´Donnell (Canada) - To review the vast physiological heterogeneity of COPD, not captured by simple spirometry - To evaluate the clinical utility of lung volume measurements and inspiratory capacity - To examine the role of walk tests and laboratory-based exercise tests in the
- 4. 4 Session Learning objectives management of patients with COPD COPD phenotypes: which and what should be assessed? Professor William MacNee (UK) - Understand what should be assessed and what needs to be measured to identify different phenotypes in COPD - Understand how the identification of different phenotypes might influence the future management of COPD - Understand current gaps in the assessment of COPD Day 2: Saturday 16 November 2013 (afternoon sessions) Session Learning objectives Module 2: COPD: the patient perspective The importance of COPD symptoms Professor Paul Jones (UK) - To understand the nature of COPD symptoms, their assessment and their impact on quality of life Physical activity and COPD Professor Henrik Watz (Germany) - To understand how to assess a patient’s physical activity, what tools are available and how to interpret the measurements - To understand how physical activity impacts on a patient’s prognosis - Learn how improvements in physical activity can be achieved by pharmacotherapy, counselling and rehabilitation Rehabilitation and personalised medicine: the Ciro+ experience. Professor Emiel Wouters (The Netherlands) - To understand how COPD management was organised at CIRO, with the aim of improving patient outcomes and providing effective care - Learn how to map COPD comorbidities and understand the importance of personalised management strategies for patients with complex COPD - Be able to identify different COPD phenotypes The pharmacology of different bronchodilators, can they enhance one another? Professor Mario Cazzola (Italy) - To understand the rationale for combining LAMAs and LABAS - To understand when to add a second bronchodilator with a different mechanism of action to current therapy - Be able to identify which patients benefit most from bronchodilator combination
- 5. 5 Session Learning objectives therapy i.e. need maximal bronchodilation The importance of delivery systems Professor Paul Jones (UK) - To understand factors that influence inhaler performance, - To understand the importance of critical errors in inhaler use - To understand the importance of reliable drug delivery Day 3: Sunday 17 November 2013 Session Learning objectives Module 3: Exacerbations of COPD Exacerbations: knowns and unknowns Professor Wisia Wedzicha (UK) - To understand the etiology and timecourse of exacerbations, and the impact of exacerbations to the patient - To understand the role of bronchodilators in the prevention of exacerbations and how to use them - To understand how long-term antibiotic therapy can be used to prevent exacerbations - To understand the role of LABA/ICS in the prevention of exacerbations Diagnosis, biomarkers and heterogeneity Professor Ian Pavord (UK) - Understand the clinically important phenotypes of COPD exacerbations - Be able to identify potentially helpful biomarkers at the time of exacerbation - Understand how biomarkers could be used to direct treatment and prevent exacerbations Treatment of exacerbations -room for improvement? Professor Pierre R. Burgel (France) - To understand the prognostic impact of severe exacerbations - Be able to identify which patients with severe exacerbations, who present at hospital, could be managed at home with support - Understand which patients would benefit from oral corticosteroids. What dose, and for how long? Prevention – what can we do? Professor Klaus Rabe (Germany) - To understand the risks and overall impact of exacerbations and the necessity to prevent exacerbations - To understand the concept of treating comorbid conditions to prevent
- 6. 6 Session Learning objectives exacerbations of the lung component of COPD - To understand global trends in the prevalence, severity and risk factors for COPD - To learn about mechanisms of COPD exacerbations that may lead to novel interventions
- 7. 7 First Lung Disease Summit – program (1) Day 1 (Friday, 15 November) DELEGATE ARRIVALS 17:00-19:00 Poster session
- 8. 8 First Lung Disease Summit – program (2) Day 2 (Saturday, 16 November) 09:00-09:05 Welcome Carlos Robalo Cordeiro, Portugal 09:05 – 09:30 Chair’s introduction Alvar Agusti, Spain 09:30-13:00 Module 1 - Diagnosis and assessment of COPD: beyond FEV1 Alvar Agusti, Spain 09:30- 10:00 COPD and asthma are different diseases Peter Lange, Denmark 10:00-10:30 COPD and asthma are some of the same Neil Barnes, UK 10:30 – 11:00 Break 11:00 – 11:30 Lung function and exercise tests – which methods tell us what? Denis O’Donnell, Canada 11:30-12:00 COPD phenotypes: which and what should be assessed? Bill MacNee, UK 12:00 – 13:00 Panel discussion All Module 1 speakers 13:00 – 14:00 LUNCH 14:00 – 17:35 Module 2 – COPD: the patient perspective Alvar Agusti, Spain 14:00-14:25 The importance of COPD symptoms Paul Jones, UK 14:25-14:50 Physical activity and COPD Henrik Watz, Germany 14:50-15:15 Rehabilitation and personalised medicine: the Ciro+ experience Emiel Wouters, the Netherlands 15:15-15:45 Break 15:45-16:10 The pharmacology of different bronchodilators, can they enhance one another? Mario Cazzola, Italy 16:10-16:35 The importance of delivery systems Paul Jones, UK 16:35-17:35 Panel discussion All Module 2 speakers 17:35-17:45 Wrap-up Alvar Agusti, Spain
- 9. 9 Day 2 (Sunday, 17 November) 09:00-09:05 Welcome back TBC 09:05-12:30 Module 3 – Exacerbations of COPD Paul Jones, UK 09:05 – 09:35 Exacerbations: knowns and unknowns Wisia Wedzicha, UK 09:35- 10:05 Diagnosis, biomarkers and heterogeneity Ian Pavord, UK 10:05-10:35 Treatment of exacerbations - room for improvement? Pierre Burgel, France 10:35– 11:00 Break 11:00 – 11:30 Prevention - what can we do? Klaus Rabe, Germany 11:30-12:30 Panel discussion All Module 3 speakers 12:30 – 13:00 Close Alvar Agusti, Spain 13:00 – 14:00 LUNCH DELEGATE DEPARTURES First Lung Disease Summit – program (3)